Pharmaceutical

Navigator gains $100m in Series A funding for antibody therapeutics

Navigator Medicines has secured $100m in a Series A financing round with the aim of advancing bispecific antibody therapeutics.

Aug 29, 2024 - 04:00
Navigator gains $100m in Series A funding for antibody therapeutics
Navigator Medicines has secured $100m in a Series A financing round with the aim of advancing bispecific antibody therapeutics.
Read the original article

Tags:

Previous Article

Oesophageal cancer: the global clinical trials landscape in 2024

Next Article

EC approves Astellas’ PADCEV for urothelial cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Gilead signs agreements to facilitate access to HIV prevention drug

Gilead signs agreements to facilitate access to HIV pre...

Oct 4, 2024

Medicare holds firm on Alzheimer’s drug coverage policy

Medicare holds firm on Alzheimer’s drug coverage policy

Jun 2, 2023

Fresh produce access boosts health outcomes among diabetes patients and those on Medicaid in recent studies

Fresh produce access boosts health outcomes among diabe...

Nov 15, 2023